Holen Sie sich die Stockscreener-App
243.91
2.85%
-7.16
Schlusskurs vom Vortag:
$251.07
Offen:
$249.71
24-Stunden-Volumen:
508.88K
Relative Volume:
0.71
Marktkapitalisierung:
$16.00B
Einnahmen:
$1.01B
Nettoeinkommen (Verlust:
$581.90M
KGV:
27.49
EPS:
8.8733
Netto-Cashflow:
$50.57M
1W Leistung:
-3.92%
1M Leistung:
-8.55%
6M Leistung:
+7.88%
1J Leistung:
+40.58%
1-Tages-Spanne:
$243.30
$252.46
1-Wochen-Bereich:
$243.30
$260.22
52-Wochen-Spanne:
$171.90
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Firmenname
Ascendis Pharma A S
Sektor
Branche
Telefon
-
Adresse
-
Compare ASND vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
243.91 | 16.62B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-17 | Eingeleitet | Raymond James | Strong Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | UBS | Buy |
| 2024-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-06-25 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Eingeleitet | Stifel | Buy |
| 2023-12-20 | Eingeleitet | Jefferies | Buy |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Neutral |
| 2023-04-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-04-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-08-30 | Fortgesetzt | Berenberg | Buy |
| 2022-03-28 | Fortgesetzt | Wedbush | Outperform |
| 2022-03-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-03-01 | Eingeleitet | Citigroup | Buy |
| 2022-02-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-06 | Eingeleitet | Cowen | Market Perform |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-20 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-30 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-03-11 | Fortgesetzt | Stifel | Buy |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2019-03-25 | Eingeleitet | Evercore ISI | Outperform |
| 2019-01-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-01-24 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | Eingeleitet | Stifel | Buy |
| 2018-04-02 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2017-03-09 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | Eingeleitet | Credit Suisse | Outperform |
| 2016-09-26 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Ascendis Pharma A S Aktie (ASND) Neueste Nachrichten
ASND|Ascendis Pharma A/S|Price:253.204|Chg%:-0.656 - TradingKey
Ascendis Pharma A/S Revenue Breakdown – NASDAQ:ASND - TradingView
Ascendis Pharma A/S (ASND) Cash Flow - TradingKey
Ascendis Pharma A/S (ASND) Valuation: PE, PB & Fair Value Analysis - TradingKey
ASND|Ascendis Pharma A/S|Price:256.235|Chg%:+2.375 - TradingKey
Ascendis Pharma A/S (ASND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ascendis Pharma A/S (ASND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artisan Small Cap Fund Trimmed Ascendis Pharma (ASND) Amid Lawsuit Concerns - Yahoo Finance
Ascendis Pharma AS (STU:A710) Shiller PE Ratio : (As of Jul. 24, 2026) - GuruFocus
Goldman Sachs Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $300 - 富途牛牛
Ascendis Pharma (ASND) Could Be 14% Below Fair Value As Growth Hopes Hold - simplywall.st
Ascendis Pharma (ASND) Shows High Growth Momentum With Bull Flag Breakout Setup - ChartMill
Ascendis Pharma A/S (ASND) Stock Analysis: Unpacking a 15.68% Potential Upside for Investors - DirectorsTalk Interviews
Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on February 12, 2025. - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
(ASND) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ASND5566766 Bond Profile — Key Metrics - TradingView
Price to earnings forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Ascendis Pharma (ASND) grants 14,060 employee warrants at $265.57 - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND) and Erasca (ERAS) - The Globe and Mail
Price to book forward of Ascendis Pharma A/S – DUS:A710 - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.com - Investing.com India
Enterprise value to EBITDA forward of Ascendis Pharma A/S – DUS:A710 - TradingView
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $306 - Moomoo
BofA raises Ascendis Pharma stock price target on revenue outlook - Investing.com
Ascendis Pharma: Precision in Princeton - New Jersey Business Magazine
Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Giant with 144% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Price to sales forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Enterprise value to EBIT forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Reports Two Year YUVIWEL Trial Data In Achondroplasia - Yahoo Finance
Enterprise value to revenue forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong - simplywall.st
Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24% - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to revenue forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Enterprise value to EBITDA forward of Ascendis Pharma A/S – BIVA:ASND1/N - TradingView
Ascendis Pharma : ASND - 24/7 Wall St.
Ascendis Pharma Stock's Strong Momentum to Continue, Wedbush Says - Moomoo
Wedbush Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $327 - Moomoo
Ascendis Pharma (ASND) Investor Update Summary - Quartr
Ascendis Pharma (ASND) Q3 2025 earnings summary - Quartr
Ascendis Pharma (ASND) Q3 2024 earnings summary - Quartr
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345 - Moomoo
Ascendis Pharma (ASND) Study Update Summary - Quartr
RBC Capital Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $280 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
RBC Capital Adjusts Ascendis Pharma Price Target to $280 From $275, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Stock Analysis: Strong Buy Ratings and Promising Revenue Growth Capture Investor Interest - DirectorsTalk Interviews
ASNDAscendis Pharma A/S Volatility & Greeks - Finviz
Ascendis Pharma (ASND) Could Be 7% Undervalued Following Fresh ApproaCH Trial Data - simplywall.st
Finanzdaten der Ascendis Pharma A S-Aktie (ASND)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ascendis Pharma A S-Aktie (ASND) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
May 29 '26 |
Buy |
223.12 |
500 |
111,562 |
900 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer |
May 29 '26 |
Buy |
223.32 |
250 |
55,830 |
4,267 |
| BIENAIME JEAN JACQUES | Director |
May 26 '26 |
Buy |
237.80 |
400 |
95,120 |
400 |
| JENSEN FLEMMING STEEN | See Remarks |
May 11 '26 |
Sale |
238.49 |
19,460 |
4,641,021 |
0 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):